Core Viewpoint - Kahn Swick & Foti, LLC is investigating Five Below, Inc. for potential breaches of fiduciary duties and violations of laws following a decline in sales and the departure of key executives [1][4]. Financial Performance - Five Below reported a 5.0% decrease in comparable sales for the period ending July 15, 2023, compared to the previous year [2]. - The company expects fiscal second-quarter sales to be between $820 million and $826 million, anticipating a 6% to 7% decrease in comparable sales [2]. Legal Issues - Following the sales decline, Five Below and its executives are facing a securities class action lawsuit for failing to disclose material information, with the court allowing the case to proceed [3]. - KSF's investigation is focused on whether the company's officers and directors violated their fiduciary duties to shareholders [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

Core Viewpoint - The Beauty Health Company is under investigation by Kahn Swick & Foti, LLC due to potential breaches of fiduciary duties by its officers and directors following disappointing financial results and a securities class action lawsuit [1][3]. Financial Performance - In November 2023, Beauty Health reported third-quarter financial results that were negatively impacted by lower-than-expected U.S. revenue and incurred $63.1 million in restructuring charges related to device upgrades [2]. - The company revised its fiscal year 2023 net sales guidance to a range of $385 million to $400 million and adjusted its EBITDA margin guidance to 5% to 6%, while suspending its long-term financial outlook for 2025 [2]. Legal Issues - Following the financial disclosures, Beauty Health and certain executives were sued in a securities class action lawsuit for failing to disclose material information, which is currently ongoing [3]. - KSF's investigation is focused on whether the company's officers and/or directors violated state or federal laws or breached their fiduciary duties to shareholders [3].

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices i ...

Core Viewpoint - Galectin Therapeutics Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after an FDA communication regarding its drug development program [1][3]. Group 1: Company Developments - On December 19, 2025, Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on the same day [3].

Core Insights - Ultragenyx Pharmaceutical Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III studies for setrusumab (UX143) in Osteogenesis Imperfecta [1][2] - The studies did not meet their primary endpoints, leading to a significant drop in Ultragenyx's stock price [2][3] Group 1: Study Results - The Phase III Orbit and Cosmic studies failed to achieve their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates, respectively [2] - Although secondary endpoints showed improvements in bone material density, these did not correlate with a statistically significant reduction in fractures [2] Group 2: Market Reaction - Following the announcement of the study results, Ultragenyx's stock price fell by $14.87, a decrease of 43.49%, opening at $19.32 per share [3] - This decline has resulted in the stock reaching a new 52-week low, significantly below the previous low of $25.81 [3] Group 3: Company Response - Ultragenyx has indicated that it will implement significant expense reductions in response to the study outcomes [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sprouts Farmers Market, Inc. due to allegations of misleading statements regarding the company's growth potential and sales performance, which may have led to inflated stock prices for investors [2][5]. Company Performance - Sprouts Farmers Market reported a 4.3% decrease in comparable store growth for Q3 fiscal 2025 compared to the previous quarter, which was below the company's prior projections [6]. - The company has revised its full-year sales growth expectations down from 7.5%-9% to 7%, attributing the shortfall to challenging year-over-year comparisons and a softening consumer [6]. Legal Proceedings - A federal securities class action has been filed against Sprouts, with a deadline of January 26, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Sprouts and its executives made false and misleading statements while failing to disclose material adverse facts about the company's growth potential [5]. Stock Market Impact - Following the announcement of disappointing Q3 results, Sprouts' stock price fell by $22.64, opening at $81.91 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for allegedly making materially false and misleading statements regarding the company's Long Island City property and its leasing value as a life-science destination during the Class Period from January 27, 2025, to October 27, 2025 [3][7]. Allegation Details - The lawsuit claims that the defendants provided overwhelmingly positive statements while concealing adverse facts about the true state of the Long Island City property [3]. - It is alleged that the company's claims regarding the leasing value of the LIC property were misleading and lacked a reasonable basis, particularly concerning the Megacampus™ strategy [3]. - As a result, the defendants' statements about the company's business, operations, and prospects were materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Alexandria shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - There is no cost or obligation for investors to inquire about their legal options [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - Klarna Group plc is facing a securities class action lawsuit for failing to disclose material information during its IPO, which has led to substantial losses for investors [1][3]. Group 1: Lawsuit Details - Investors who purchased Klarna's securities during its September 2025 IPO have until February 20, 2026, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Eastern District of New York, under the case name Nayak v Klarna Group Plc., et al., No. 25-cv-7033 [3][5]. - The allegations include that Klarna materially understated the risk of increasing loss reserves shortly after the IPO, which was known or should have been known to the company [4]. Group 2: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case [5]. - The firm has been recognized among the top 10 nationally based on total settlement value, indicating its strong reputation in handling securities litigation [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. due to significant stock losses and possible misleading statements made by the company [2][5]. Group 1: Company Overview - Beta Bionics, Inc. is listed on NASDAQ under the ticker BBNX [2]. - The company experienced a significant stock decline of approximately 37% on January 9, 2026, following an announcement regarding lower-than-expected patient starts for the fourth quarter [5]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi focuses on whether Beta Bionics issued misleading statements or failed to disclose important information that could affect investors [5]. - Investors who suffered significant losses are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1].